Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.05%
0%
-19.05%
6 Months
-22.73%
0%
-22.73%
1 Year
-15.0%
0%
-15.0%
2 Years
-59.52%
0%
-59.52%
3 Years
-68.52%
0%
-68.52%
4 Years
-76.39%
0%
-76.39%
5 Years
-5.56%
0%
-5.56%
VentriPoint Diagnostics Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.11%
EBIT Growth (5y)
-161.54%
EBIT to Interest (avg)
-3.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
-0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.42
EV to EBIT
-4.61
EV to EBITDA
-4.68
EV to Capital Employed
-8.53
EV to Sales
19.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2012
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.20
-1.40
14.29%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-1.40
7.14%
Operating Profit Margin (Excl OI)
0.00%
-45,095.80%
4,509.58%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 7.14% vs -27.27% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-4.70
-4.90
4.08%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.90
-4.90
Operating Profit Margin (Excl OI)
-50,454.10%
-100,248.00%
4,979.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
About VentriPoint Diagnostics Ltd. 
VentriPoint Diagnostics Ltd.
Pharmaceuticals & Biotechnology
Ventripoint Diagnostics Ltd., formerly Luca Capital Inc., is a medical device company. The Company is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. By using images produced from existing medical imaging systems, the Ventripoint Medical System (VMS) generates accurate heart volumetric measurements and a three-dimensional (3D) model in a rapid and inexpensive manner. The Company's solution produces critical heart information by processing standard information received from existing medical imaging equipment with its methods incorporating Knowledge Based Reconstruction (KBR) algorithms and cardiac databases (catalogues). Its technology platform is applicable to all heart diseases. The Company has developed prototype analytical software package to be used with 4D echocardiograms (VMS-4DE) and one to be used with magnetic resonance imaging (MRI) images (VMS-CMR). It also focuses on developing VMS-Plus and the VMS-Nano.
Company Coordinates 
Company Details
2 Sheppard Ave E , NORTH YORK ON : M2N 5Y7
Registrar Details






